MSN Laboratories Private Limited

I'll verify the company's profile with web searches.

Let me verify the litigation context.

Company overview. MSN Laboratories Private Limited (commonly "MSN Labs" or "MSN Group") is a privately held Indian pharmaceutical manufacturer headquartered in Hyderabad, Telangana, with a registered office in Sanath Nagar. It was incorporated on 27 August 2003 and began operations in 2004, founded by Dr. Manne Satyanarayana Reddy, who remains Chairman and Managing Director. It is not publicly traded. Size estimates vary by source: company materials cite over 15,000 employees, a 2026 founder interview cited roughly 18,500 staff plus contract workers and group turnover above ₹10,000 crore, while third-party trackers (Crustdata, SignalHire) place headcount near 9,000–10,000. Revenue figures are company-reported and should be treated as approximate.

Products / operations. MSN manufactures active pharmaceutical ingredients (APIs) and finished dosage forms (generic formulations), and provides contract research and manufacturing services (CRAMS/CDMO). Its portfolio spans oncology, cardiology, CNS, diabetes, nephrology, urology, gastroenterology and orthopaedics — roughly 35 therapeutic areas. The group reports 17 API and 8 finished-dosage facilities across India, the US, Indonesia and UAE, plus integrated R&D centers. Its wholly owned US subsidiary, MSN Pharmaceuticals Inc., handles US generic development and manufacturing; the company has been a leading filer of US drug master files and has filed 200+ ANDAs.

Patent-litigation posture. This is an operating company, not an NPE or shell licensor. The tracked data show 0 cases as plaintiff and 1 as defendant — the classic profile of a generic manufacturer defending Hatch-Waxman infringement claims rather than asserting patents.

Notable case. The sole tracked matter is Celgene Corp. v. MSN Laboratories Private Limited et al., No. 2:22-cv-01993 (D.N.J., filed 6 April 2022), concerning lenalidomide (Revlimid) patents (including U.S. 8,198,262; 8,735,428; 9,993,467; 10,555,939). MSN Pharmaceuticals Inc. was a co-defendant. Judge Esther Salas entered a consent judgment on 15 June 2022 enjoining MSN from infringing the patents-in-suit and dismissing claims with prejudice — a prompt settlement consistent with the wave of Revlimid ANDA suits Celgene filed against numerous generics in this venue.